Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:NCNA

NuCana Q2 2025 Earnings Report

NuCana logo
$1.52 -0.01 (-0.65%)
As of 08/21/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

NuCana EPS Results

Actual EPS
-$0.16
Consensus EPS
-$2.75
Beat/Miss
Beat by +$2.59
One Year Ago EPS
N/A

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NuCana Announcement Details

Quarter
Q2 2025
Date
8/20/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NuCana Earnings Headlines

NuCana Files Q2 2026 Results and Updates U.S. Registration Statements
August 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NCNA/pressreleases/3859915/nucana-files-q2-2026-results-and-updates-us-registration-statements/
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344884/0/en/nucana-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
NuCana plc Sponsored ADR
June 16, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/NCNA
NuCana Appoints Ian Webster as Chief Financial Officer
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304314/0/en/nucana-appoints-ian-webster-as-chief-financial-officer.html
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295318/0/en/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update.html
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients.

Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.

View NuCana Profile
Earnings Tools